middle.news
Immutep Suspends Trading Ahead of Crucial Phase III Trial Update
10:22am on Wednesday 11th of March, 2026 AEDT
•
Healthcare
Read Story
Immutep Suspends Trading Ahead of Crucial Phase III Trial Update
10:22am on Wednesday 11th of March, 2026 AEDT
Key Points
Voluntary suspension requested by Immutep Limited
Suspension linked to interim futility analysis of TACTI-004 Phase III trial
Eftilagimod alfa is the lead candidate under evaluation
Suspension effective immediately, lasting until announcement or 13 March 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE